The new Ad26 / MVA and Ad35 / Ad26 vector - based
vaccine regimens resulted in over 80 % reduction in the per - exposure probability of acquisition of infection against repetitive challenges of SIV, a virus similar to HIV that infects monkeys.
Not exact matches
Though these particular
vaccine regimens are not intended for the clinic, the
results suggest that effective
vaccines for MERS could be developed from the Spike protein, says study coauthor Barney Graham, a vaccinologist at the National Institute of Allergy and Infectious Diseases in Bethesda, Md..
Results from an initial study to ensure that the RV144
vaccine regimen is safe and well - tolerated in South African volunteers were reported at the 2014 HIV Research for Prevention (R4P) conference.
The development track will begin with a Phase I trial to test the
vaccine regimen's safety and immunogenicity and depending on those study
results, a larger efficacy study will follow.
At the first plenary session of AIDS
Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV inf
Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the
results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost
vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV inf
vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infection.